Clinical and Biological Predictors of Severe Palbociclib- Induced Neutropenia in Patients with Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: A Retrospective Single-Center Study
Background: Palbociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, is a standard treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer. However, severe neutropenia remains its most common dose-limiting toxicity. This study aimed to determi...